SILO PHARMA INC (SILO) Stock Price & Overview

NASDAQ:SILOUS82711P2011

Current stock price

0.3456 USD
+0 (+0.49%)
At close:
0.376 USD
+0.03 (+8.8%)
After Hours:

The current stock price of SILO is 0.3456 USD. Today SILO is up by 0.49%. In the past month the price decreased by -1.26%. In the past year, price decreased by -68%.

SILO Key Statistics

52-Week Range0.221 - 1.19
Current SILO stock price positioned within its 52-week range.
1-Month Range0.29 - 0.3991
Current SILO stock price positioned within its 1-month range.
Market Cap
4.603M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.93
Dividend Yield
N/A

SILO Stock Performance

Today
+0.49%
1 Week
-8.81%
1 Month
-1.26%
3 Months
+2.98%
Longer-term
6 Months -50.43%
1 Year -68.00%
2 Years -81.19%
3 Years -83.93%
5 Years N/A
10 Years N/A

SILO Stock Chart

SILO PHARMA INC / SILO Daily stock chart

SILO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SILO. When comparing the yearly performance of all stocks, SILO is a bad performer in the overall market: 90.64% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SILO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SILO. While SILO has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SILO Earnings

Next Earnings DateMay 7, 2026
Last Earnings DateMar 26, 2026
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

SILO Forecast & Estimates


Analysts
Analysts82.86
Price TargetN/A
EPS Next Y-25%
Revenue Next Year0%

SILO Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

SILO Financial Highlights

Over the last trailing twelve months SILO reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 21.56% compared to the year before.


Income Statements
Revenue(TTM)72.00K
Net Income(TTM)-5.08M
Industry RankSector Rank
PM (TTM) N/A
ROA -79.51%
ROE -101.36%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%44.88%
Sales Q2Q%0%
EPS 1Y (TTM)21.56%
Revenue 1Y (TTM)0%

SILO Ownership

Ownership
Inst Owners9.11%
Shares13.32M
Float13.10M
Ins Owners1.67%
Short Float %2.44%
Short Ratio0.28

About SILO

Company Profile

SILO logo image Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Company Info

IPO: 2012-01-05

SILO PHARMA INC

677 N Washington Blvd

Sarasota FLORIDA US

Employees: 3

SILO Company Website

SILO Investor Relations

Phone: 17184009031

SILO PHARMA INC / SILO FAQ

What does SILO do?

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.


What is the stock price of SILO PHARMA INC today?

The current stock price of SILO is 0.3456 USD. The price increased by 0.49% in the last trading session.


Does SILO stock pay dividends?

SILO does not pay a dividend.


What is the ChartMill rating of SILO PHARMA INC stock?

SILO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the number of employees for SILO PHARMA INC?

SILO PHARMA INC (SILO) currently has 3 employees.


What is SILO PHARMA INC worth?

SILO PHARMA INC (SILO) has a market capitalization of 4.60M USD. This makes SILO a Nano Cap stock.


What is the Short Interest ratio of SILO PHARMA INC (SILO) stock?

The outstanding short interest for SILO PHARMA INC (SILO) is 2.44% of its float.